Hair Loss Treatments For Women In Weston, FL
Revive 365 Wellness sees women for hair loss. Topical minoxidil is the only drug the FDA has approved for female pattern hair loss, and the published timeline is at least 4 months to visible growth, optimally 6 to 12. Women who stop see growth return to baseline over about 4 months, so the hair gained is the hair lost. Two things should be settled before that clock starts: whether a temporary shed is sitting on top of the pattern, and whether the pattern is scarring rather than thinning.
In-person and telehealth appointments available
The Treatment Clock
Every option for female hair loss has a point before which it cannot be judged. Four checkpoints matter, and the reason women abandon treatment is that they are told about none of them.
Week 0. What has to be settled before the clock starts
Two questions, and both change the timeline rather than the treatment. Is a temporary shed sitting on top of the pattern, and is the pattern scarring. Both sections below cover these. Settle them first, because starting a 12-month drug on top of an unrecognized shed produces a result nobody can read at month 6.
Weeks 2 to 12. The window where side effects declare themselves
Each option puts its early effects on a different schedule, and the schedule is published for the oral route. The 2025 JAMA Dermatology consensus panel agreed that lightheadedness and heart-rate changes on low-dose oral minoxidil tend to appear within 3 to 7 days, at 79.1 percent agreement, and that fluid-retention signs such as swollen feet or legs, facial swelling and weight gain tend to appear at 4 to 6 weeks, at 93.0 percent. Knowing which week each belongs to is what separates an expected effect from a reason to call.
A temporary increase in shedding on starting a topical also sits in this window, and it settles. What matters here is the calendar: it lands early, it is not the drug failing, and it resolves well before the first checkpoint that can be read.
Month 4. The floor
This is the earliest point at which topical minoxidil can be judged. Olsen and colleagues, writing in the Journal of the American Academy of Dermatology in 2025, put it plainly: “Visible hair growth takes at least 4 mo, optimally 6-12 mo.” The Women’s Rogaine 5 percent foam label says results may appear at 3 months and that some women need 6 months of once-daily use. The 2 percent solution label asks for at least 4 months of twice-daily use.
A woman at week 8 has not failed treatment. She has not finished starting it. Anyone selling visible change in 6 weeks is selling a timeline the drug does not have.
Months 6 to 12. The real read
This is where the published trials take their measurements, which is why it is where you should take yours. The registration trial comparing 5 percent foam once daily against 2 percent solution twice daily in 113 women read out at 24 weeks. Photograph your part line in the same light at month 0, month 6 and month 12, and judge from the photographs rather than the mirror. Hair changes too slowly for memory to be a reliable instrument.
The shed you may be sitting on: GLP-1 medications and rapid weight loss
If you started a GLP-1 or lost weight quickly in the last year, that belongs in the first 5 minutes of your appointment. Both leading labels list hair loss, and the tirzepatide label reports it far more often in women than in men.
The Zepbound prescribing information, revised January 2026, states that “Hair loss adverse reactions in ZEPBOUND-treated patients were associated with weight reduction.” The same paragraph reports that “In a pool of Study 1 and 2, hair loss was reported more frequently in female than male patients in the ZEPBOUND (7.1% female versus 0.5% male) and placebo (1.3% female versus 0% male) treatment groups.” The Wegovy label, revised February 2026, lists hair loss in 3 percent of adults on 2.4 mg once weekly, out of 2,116, against 1 percent on placebo, out of 1,261.
A University of Pennsylvania team published a target trial emulation in The BMJ on July 22, 2026, using the Penn Medicine electronic health record across 5 hospitals. In adults with type 2 diabetes starting a GLP-1, recorded alopecia of any type ran higher than in patients starting a comparator: hazard ratio 1.37, with a 95 percent confidence interval of 1.08 to 1.73, against SGLT-2 inhibitors, and 1.68, interval 1.28 to 2.20, against DPP-4 inhibitors. The subtype analysis found the association specific to non-scarring alopecia, at 1.53 and 1.72 against those same comparators. In the SGLT-2 comparison, weighted incidence was 6.91 versus 5.04 cases per 1,000 person-years. Carry the authors’ own framing with the numbers: “Although the absolute risk is low, awareness of this potential effect may help to inform treatment decisions.”
The mechanism is well described. StatPearls lists crash dieting and low protein intake among telogen effluvium triggers. A 2024 study in Annals of Dermatology of 140 patients with weight-loss-associated telogen effluvium, 110 of them women, recorded mean weight loss of 15.2 percent at about 3.5 kilograms per month, and concluded that “Women and older adults are especially vulnerable to TE, even if the degree of weight loss is not more severe than in men and young adults.”
The timing is the part that misleads people. StatPearls describes the causative event as occurring “approximately 3 months before the onset of the shedding,” with a range of 1 to 6 months. So the shed that started this month traces to something that happened in spring. Women routinely date it to the wrong cause, blame the wrong thing, and start a hair drug against a shed that was going to settle on its own.
What this changes on the clock: a shed running underneath a new treatment makes month 6 unreadable. Where the history points to one, we set the clock differently and say so. We run medical weight loss in the same practice, so protein intake, rate of loss and hair timing are one conversation rather than 3.
None of this is a reason to stop a medication that is working for your metabolic health, and we will not tell you to. It is a reason to plan the hair timeline around it.
Frontal fibrosing alopecia, the pattern where the clock never starts
One pattern of female hair loss does not respond to time on any treatment, because the follicle is gone rather than shrinking. It recedes as a band across the front and sides, and the eyebrows usually go with it.
The American Academy of Dermatology states it in one sentence: “Once a hair follicle scars, it can no longer grow hair.”
Frontal fibrosing alopecia is the scarring pattern most often mistaken for an ordinary receding hairline in women. StatPearls describes it as mainly affecting women after menopause, typically around age 60, and reports partial or total eyebrow loss in 81 percent of patients in Kossard’s series and 100 percent in more recent series. The AAD puts the eyebrow figure at 80 to 95 percent of diagnosed women. StatPearls also notes that “the diagnosis is exclusively clinical,” with histology reserved for unclear cases.
Two details make this worth screening for in this city rather than assuming past. Census QuickFacts puts Weston at 69,588 residents as of July 2025, 52.6 percent female, with 11.9 percent aged 65 and over. And the OTC topical minoxidil label directs use to regrow hair on the top of the scalp at the vertex, stating it is not intended for frontal baldness or a receding hairline. So the one drug approved for women is labeled away from the exact area this condition attacks.
If your hairline is moving as a band and your eyebrows are thinning, the person you need is a dermatologist who will examine and, where needed, biopsy. We make that referral rather than starting a plan that cannot work.
What happens when you stop
Stopping minoxidil returns your hair to where it would have been untreated, over about 4 months. The hairs you gained are the ones you lose.
Olsen and colleagues put the figure in the 2025 JAAD paper: “Discontinuation of TMS or TMF will lead to return to baseline hair growth over 4 mo.” TMS and TMF are topical minoxidil solution and foam. The Women’s Rogaine foam label carries the same warning in consumer language, that continued use is necessary to keep regrowth or hair loss will begin again.
The original demonstration is older and narrower, and its limits belong on the page. Olsen and Weiner published it in JAAD in 1987 in 10 men with male pattern baldness on 2 or 3 percent minoxidil. Hair counts roughly doubled on treatment, most of the recruited hairs were lost after stopping, and 4 of the 10 finished below where they started. Ten men, forty years ago, at concentrations no longer typical. Read it as mechanism rather than as a number about women.
Stopping is common, though the figure circulating online is misused. A 2023 retrospective review of 400 androgenetic alopecia patients at a single private clinic in Jeddah, Saudi Arabia found 86.3 percent had discontinued topical minoxidil. That number gets quoted as a statistic about women. The paper reports the opposite: “Discontinuation rate showed no association with sex.”
I have watched this play out in consults more than once. A woman uses a topical for 2-3 years, starts hormone therapy, drops the minoxidil assuming the hormones will cover it, then restarts months later on a stylist’s advice. She sheds hard and reads the shed as the drug failing her. It is the clock restarting on a scalp that has already given the hair back.
So if a routine is not fitting your life, the conversation to have is about changing the formulation or the route, months before the bottle goes in a drawer.
The lab number to settle before month one
Ask which ferritin cutoff your result was measured against, because four are in print and they do not agree.
The World Health Organization’s 2020 guideline uses below 15 micrograms per litre to define iron deficiency in apparently healthy individuals aged 5 years and over, and below 70 in adults when infection or inflammation is present. The 2023 clinical review in Cutis by Zhang, LaSenna and Shields recommends 40 or lower in otherwise healthy patients with hair loss. That same review cites work by Moeinvaziri and colleagues reporting an odds ratio for telogen effluvium of 21.0, with a 95 percent confidence interval of 4.2 to 105.0, at a threshold of 30 or lower.
Ferritin rises with inflammation, which is exactly why WHO publishes a second and much higher cutoff for anyone with infection or inflammation running. The Cutis authors also draw a line between conditions: iron status may play a role in telogen effluvium, and there is insufficient evidence that low iron status impacts androgenetic alopecia.
The 50 and 70 nanogram per millilitre “optimal for hair” targets repeated across clinic sites and supplement marketing could not be traced to a peer-reviewed dermatology cutoff. We do not use them as targets.
This belongs at week 0 rather than month 6, because an unaddressed deficiency running underneath a treatment is another reason the month-6 photograph will not read cleanly.
Real Patient Results
Microneedling + PRF + Exosomes — After 2 Sessions
Results vary by individual and treatment plan
How we set your clock at the first appointment
The first appointment is an evaluation, and it ends with a timeline in months rather than a package. You will not be treated that day.
Before you come in
Photograph your part line and hairline in the same bathroom light, from the same angle, 3 days running. Bring the photos. Bring any lab work from the past 12 months even if you were told it was normal, plus a list of every medication and supplement, including GLP-1s, hormone therapy, and anything you started or stopped this year.
In the room
Scalp and pattern assessment. History against the week 0 questions above, with weight change and GLP-1 use covered specifically. Where a hormonal, thyroid, or iron cause is in play, we order labs and wait for the results before setting a timeline.
What you leave with
A written timeline naming the checkpoint at which the plan gets judged, the photograph protocol, and what would make us tell you to stop. Where a prescription belongs in the plan, we either write it or refer you to a prescriber who will, and we say which at the appointment rather than after it.
Frequently Asked Questions
I am 8 weeks in and I see nothing. Should I stop?
No. 8 weeks is inside the window where nothing is expected to be visible. Olsen and colleagues put visible growth at “at least 4 mo, optimally 6-12 mo,” and the Women’s Rogaine foam label says some women need 6 months of once-daily use. Stopping at week 8 is the single most common way a first attempt gets wasted.
I am on Wegovy or Zepbound. Should I stop taking it?
Not on our advice, and not without the prescriber who manages it. Both labels list hair loss, and the Zepbound label ties it to the amount of weight lost and reports it in 7.1 percent of women against 0.5 percent of men in a pool of 2 studies. That makes it something to build the hair timeline around, including protein intake, rather than a reason to abandon metabolic care.
My shedding started about 3 months after I lost weight. Is that the cause?
The timing fits the published pattern. StatPearls describes the causative event in telogen effluvium as occurring “approximately 3 months before the onset of the shedding,” with a range of 1 to 6 months, and lists crash dieting and low protein intake among triggers. A 2024 Annals of Dermatology study of 140 patients with weight-loss-associated shedding found women particularly vulnerable. Bring the dates and the rate of loss to the appointment; they change the timeline more than they change the treatment.
I stopped minoxidil a year ago. Did I lose the progress?
Growth returns to baseline over about 4 months off treatment, per Olsen and colleagues in 2025. Restarting works. It restarts the clock rather than resuming it, and the shed that comes with restarting is expected.
My hairline is receding in a band and my eyebrows are thinning. What is that?
That combination points toward frontal fibrosing alopecia, a scarring condition, and it needs a dermatologist rather than a scalp treatment. The AAD states that once a hair follicle scars it can no longer grow hair. StatPearls reports eyebrow loss in 81 percent of patients in Kossard’s series and 100 percent in more recent series. Book with us and we will look, and if that is the pattern we refer you out at the first visit.
My ferritin came back normal. Is that the end of it?
Ask which cutoff was used. WHO uses below 15 micrograms per litre in apparently healthy individuals aged 5 and over, and below 70 in adults when infection or inflammation is present. The Cutis 2023 review recommends 40 or lower in otherwise healthy patients with hair loss. Ask also whether anything inflammatory was running when the blood was drawn, since ferritin rises with inflammation.
How should I photograph my hair to track it?
Same light, same angle, same part, at month 0, month 6 and month 12. Published trials in women measure at 24 weeks, which is why month 6 is a real checkpoint rather than an arbitrary one. Judge from the photographs. Hair changes too slowly for memory to be a reliable instrument.
When would you tell me to stop?
When the month 6 and month 12 photographs show no change on a plan you have followed, or when the evaluation says the follicle is scarred and no timeline applies. We would rather lose the appointment than start a second series against a first one that did not move.
Book an evaluation and get your timeline
One appointment, one purpose: leave with a timeline you can hold us to.
